The Polymorphisms of Osteopontin Gene and Plasma Osteopontin Protein Levels with Susceptibility to Colorectal Carcinoma

Abstract

Osteopontin (OPN) plays an important role in the development and progression of some tumors. The polymorphisms of OPN probably change its expression and contribute to interindividual differences of susceptibility to some cancers. The purpose of the present study was to explore the association of rs9138 (+1239; 3′UTR: 3′untranslated regions) and rs1126616 (+750; exon 7) polymorphisms located in the OPN gene with colorectal carcinoma (CRC) susceptibility and to investigate the correlation of the polymorphisms, plasma levels of the OPN protein, clinicopathologic parameters, tumor markers, and lipid. The genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism. The plasma levels, tumor markers, and lipid were measured by enzyme-linked immunosorbent assay. The results indicated that genotype AA and AC of rs9138 and CC and CT of rs1126616 were associated with increased risk of CRC. The allelic frequencies of rs9138A, rs1126616C, and the haplotype (A–C) were associated with increased risk of CRC. Although there was no significant difference of plasma levels in various genotypes, increased plasma protein expression in CRC patients compared with controls was found. Our results suggested that the rs9138 and rs1126616 of OPN were associated with CRC risk, and the OPN protein in plasma may be a potential tumor marker of CRC.

Get full access to this article

View all access options for this article.

References

Agrawal

et al. 2002. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst, 94:513–521.

Barizzone

et al. 2011. Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol, 72:930–934.

Bhattacharya

S.D.

et al. 2010. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery, 148:291–297.

Chin

L.J.

et al. 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res, 68:8535–8540.

Chiu

Y.W.

et al. 2010. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol, 46:302–306.

Conne

et al. 2000. The 3′ untranslated region of messenger RNA: a molecular “hotspot” for pathology? Nat Med, 6:637–641.

D'Alfonso

et al. 2005. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum, 52:539–547.

Denhardt

D.T.

et al. 1995. Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci, 760:127–142.

Dong

Q.Z.

et al. 2013. Osteopontin promoter polymorphisms at locus −443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology, 57:1024–1034.

10.

El-Tanani

M.K.

et al. 2006. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev, 17:463–474.

11.

Fedarko

N.S.

et al. 2001. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 7:4060–4066.

12.

Fritz

A.G.

2000. International Classification of Diseases for Oncology. 3rd. World Health Organization.

13.

Giacopelli

et al. 2004. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics, 20:87–96.

14.

Glas

et al. 2011. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS One, 6:e29309.

15.

Goparaju

C.M.

et al. 2010. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol, 5:1516–1523.

16.

Han

et al. 2008. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One, 3:e0001757.

17.

Huang

et al. 2012. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One, 7:e47901.

18.

Jemal

et al. 2011. Global cancer statistics. CA Cancer J Clin, 61:69–90.

19.

Landi

et al. 2008. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis, 29:579–584.

20.

Liu

Y.L.

et al. 2011. Serum LDL-C and LDL-C/HDL-C ratio are positively correlated to lymph node stages in males with colorectal cancer. Hepatogastroenterology, 58:383–387.

21.

Lumachi

et al. 2012. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res, 32:985–988.

22.

McAllister

S.S.

et al. 2008. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 133:994–1005.

23.

Notarnicola

et al. 2005. Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology, 68:371–374.

24.

Poruk

K.E.

et al. 2013. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas, 42:193–197.

25.

Rao

et al. 2013. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res, 19:785–797.

26.

Shimada

et al. 2005. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology, 68:285–292.

27.

Sobin

L.H.

et. al. 2009. TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell.

28.

Sodek

et al. 2000. Osteopontin. Crit Rev Oral Biol Med, 11:279–303.

29.

Trivedi

et al. 2011. Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus. Biomed Biotechnol, 2011:802581.

30.

Wang

K.X.

et al. 2008. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev, 19:333–345.

31.

Weber

G.F.

et al. 1997. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians, 109:1–9.

32.

Wild

et al. 2010. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res, 16:6111–6121.

33.

et al. 2011. OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark, 10:233–239.

34.

Zhao

et al. 2012. Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer, 12:477.

35.

Zheng

2006. The Basic Reserch and Practice to Colorectal Cancer. General Peoples Publishing Press, 2–4.